Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3

Odomzo

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2024-12-31
Captured
2026-09-09T23:37:39.774134+00:00
Current indication reconciliation
Not reconciled
Boxed warning in this label
  1. WARNING: EMBRYO-FETAL TOXICITY ODOMZO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. ODOMZO is embryotoxic, fetotoxic, and teratogenic in animals [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . Verify the pregnancy status of females of reproductive potential prior to initiating therapy. Advise females of reproductive potential to use effective contraception during treatment with ODOMZO and for at least 20 months after the last dose [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3) ] . Advise males of the potential risk of exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with ODOMZO and for at least 8 months after the last dose [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3) ] . WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. ODOMZO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman and is embryotoxic, fetotoxic, and teratogenic in animals. ( 5.1 , 8.1 ) Verify the pregnancy status of females of reproductive potential prior to initiating therapy. Advise females of reproductive potential to use effective contraception during treatment with ODOMZO and for at least 20 months after the last dose. ( 5.1 , 8.3 ) Advise males of the potential risk of exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with ODOMZO and for at least 8 months after the last dose. ( 5.1 , 8.3 )

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ( 1 )
Full extracted label fields
application numbers
  1. NDA205266
boxed warning exact
  1. WARNING: EMBRYO-FETAL TOXICITY ODOMZO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. ODOMZO is embryotoxic, fetotoxic, and teratogenic in animals [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . Verify the pregnancy status of females of reproductive potential prior to initiating therapy. Advise females of reproductive potential to use effective contraception during treatment with ODOMZO and for at least 20 months after the last dose [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3) ] . Advise males of the potential risk of exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with ODOMZO and for at least 8 months after the last dose [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3) ] . WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. ODOMZO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman and is embryotoxic, fetotoxic, and teratogenic in animals. ( 5.1 , 8.1 ) Verify the pregnancy status of females of reproductive potential prior to initiating therapy. Advise females of reproductive potential to use effective contraception during treatment with ODOMZO and for at least 20 months after the last dose. ( 5.1 , 8.3 ) Advise males of the potential risk of exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with ODOMZO and for at least 8 months after the last dose. ( 5.1 , 8.3 )
brand names
  1. Odomzo
current indication status
not_reconciled
dailymed set url
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=028312dc-d155-4fd5-8abd-6bb9f011d3cc
generic names
  1. SONIDEGIB
id
001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
indications and usage exact
  1. 1 INDICATIONS AND USAGE ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ( 1 )
indications and usage tables exact
    is original packager
    1. true
    manufacturer names
    1. Sun Pharmaceutical Industries, Inc.
    matched search terms
    1. carcinoma
    package ndcs
    1. 47335-303-83
    2. 47335-303-15
    product ndcs
    1. 47335-303
    product types
    1. HUMAN PRESCRIPTION DRUG
    recent major changes exact
      record type
      complete_spl_indications_section_candidate
      routes
      1. ORAL
      rxcuis
      1. 1659921
      2. 1659927
      source batch
      file
      /private/tmp/cancer-full-research/indications/raw/labels-00000.json
      meta
      disclaimer
      Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
      last updated
      2026-09-09
      results
      limit
      100
      skip
      0
      total
      830
      sha256
      0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
      url
      https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=0&sort=id%3Aasc
      source url
      https://api.fda.gov/drug/label.json?search=id%3A%22001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3%22
      spl effective date
      2024-12-31
      spl effective time
      20241231
      spl set id
      028312dc-d155-4fd5-8abd-6bb9f011d3cc
      spl version
      14
      substance names
      1. SONIDEGIB PHOSPHATE
      uniis
      1. W421AI34UW
      verification flags
      1. oncology_keyword_candidate_not_clinically_classified
      2. spl_text_not_verified_identical_to_latest_approved_label
      3. individual_indications_not_split_or_reconciled
      Drugs@FDA application source records
      1. application number
        NDA205266
        payload
        all indexed label documents
        1. Appl No
          205266
          Application Docs Date
          2016-05-17 00:00:00
          Application Docs ID
          19631
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          2
          Submission Type
          SUPPL
        2. Appl No
          205266
          Application Docs Date
          2015-07-24 00:00:00
          Application Docs ID
          40457
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          1
          Submission Type
          ORIG
        3. Appl No
          205266
          Application Docs Date
          2016-03-30 00:00:00
          Application Docs ID
          40458
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          3
          Submission Type
          SUPPL
        4. Appl No
          205266
          Application Docs Date
          2017-09-19 00:00:00
          Application Docs ID
          49776
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          4
          Submission Type
          SUPPL
        5. Appl No
          205266
          Application Docs Date
          2019-05-14 00:00:00
          Application Docs ID
          58666
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          6
          Submission Type
          SUPPL
        6. Appl No
          205266
          Application Docs Date
          2023-08-24 00:00:00
          Application Docs ID
          75278
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          9
          Submission Type
          SUPPL
        all submission records
        1. Appl No
          205266
          Review Priority
          STANDARD
          Submission Class Code ID
          7
          Submission No
          1
          Submission Status
          AP
          Submission Status Date
          2015-07-24 00:00:00
          Submission Type
          ORIG
          Submissions Public Notes
        2. Appl No
          205266
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          2
          Submission Status
          AP
          Submission Status Date
          2016-05-12 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        3. Appl No
          205266
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          3
          Submission Status
          AP
          Submission Status Date
          2016-02-17 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        4. Appl No
          205266
          Review Priority
          STANDARD
          Submission Class Code ID
          2
          Submission No
          4
          Submission Status
          AP
          Submission Status Date
          2017-09-18 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        5. Appl No
          205266
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          6
          Submission Status
          AP
          Submission Status Date
          2019-05-13 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        6. Appl No
          205266
          Review Priority
          STANDARD
          Submission Class Code ID
          3
          Submission No
          9
          Submission Status
          AP
          Submission Status Date
          2023-08-22 00:00:00
          Submission Type
          SUPPL
          Submissions Public Notes
        application number
        NDA205266
        approval interpretation
        Application linkage and approved submission are not indication-level current approval verification
        current indication status
        not_reconciled
        has approved submission record
        true
        latest approved submission date
        2023-08-22
        latest label selection rule
        max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
        latest posted label documents
        1. Appl No
          205266
          Application Docs Date
          2023-08-24 00:00:00
          Application Docs ID
          75278
          Application Docs Title
          0
          Application Docs Type ID
          2
          Submission No
          9
          Submission Type
          SUPPL
        official application record
        Appl No
        205266
        Appl Public Notes
        Appl Type
        NDA
        Sponsor Name
        SUN PHARM
        openfda application present
        true
        products
        1. Active Ingredient
          SONIDEGIB PHOSPHATE
          Appl No
          205266
          Drug Name
          ODOMZO
          Form
          CAPSULE;ORAL
          Product No
          001
          Reference Drug
          1
          Reference Standard
          1
          Strength
          EQ 200MG BASE
          marketing status
          1. Prescription

      Source passages and status connections

      Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

      Passage 1 · positive indication candidate
      application numbers
      1. NDA205266
      brand names
      1. Odomzo
      classification reasons
      1. explicit_positive_indication_predicate
      2. tumor_or_malignant_hematology_words_in_positive_statement
      clinical review status
      pending
      content role
      positive_indication_candidate
      context span
      end
      464
      end exclusive
      true
      exact text
      1 INDICATIONS AND USAGE ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or thos
      label id
      001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      dc49031419063786378da2b1d31302a59db03f1835264ddf9da927f914602e6c
      start
      0
      current approval status
      not_reconciled
      duplicate text group
      dup-5b64ee251e975da4c90b
      extraction review status
      automated_candidate_pending_source_review
      generic names
      1. SONIDEGIB
      id
      ind-span-428f568b056bae6adbb6
      label id
      001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
      positive predicate support span
      end
      55
      end exclusive
      true
      exact text
      is indicated
      label id
      001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      dc49031419063786378da2b1d31302a59db03f1835264ddf9da927f914602e6c
      start
      43
      qualifier mentions
      1. context exact
        USAGE ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has r
        kind
        age
        polarity
        not_inferred
        span
        end
        91
        end exclusive
        true
        exact text
        adult patients
        label id
        001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        dc49031419063786378da2b1d31302a59db03f1835264ddf9da927f914602e6c
        start
        77
      2. context exact
        egib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those
        kind
        stage_or_setting
        polarity
        not_inferred
        span
        end
        148
        end exclusive
        true
        exact text
        locally advanced basal cell carcinoma (BCC) that ha
        label id
        001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        dc49031419063786378da2b1d31302a59db03f1835264ddf9da927f914602e6c
        start
        97
      regulatory links
        schema version
        0.1.0
        source batch sha256
        0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
        source defined aliases
          source span
          end
          264
          end exclusive
          true
          exact text
          1 INDICATIONS AND USAGE ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
          label id
          001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          dc49031419063786378da2b1d31302a59db03f1835264ddf9da927f914602e6c
          start
          0
          source url
          https://api.fda.gov/drug/label.json?search=id%3A%22001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3%22
          spl effective date
          2024-12-31
          spl set id
          028312dc-d155-4fd5-8abd-6bb9f011d3cc
          spl version
          14
          structured fields status
          not_extracted_no_values_inferred_from_mentions
          structured indication
          age
          Source null
          approval pathway
          Source null
          biomarker and test
          Source null
          disease stage
          Source null
          limitations
          Source null
          line
          Source null
          prior therapy
          Source null
          regimen
          Source null
          tumor histology
          Source null
          use intent
          tumor_directed_candidate
          Passage 2 · positive indication candidate
          application numbers
          1. NDA205266
          brand names
          1. Odomzo
          classification reasons
          1. explicit_positive_indication_predicate
          2. tumor_or_malignant_hematology_words_in_positive_statement
          clinical review status
          pending
          content role
          positive_indication_candidate
          context span
          end
          528
          end exclusive
          true
          exact text
          reatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ( 1 )
          label id
          001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          dc49031419063786378da2b1d31302a59db03f1835264ddf9da927f914602e6c
          start
          65
          current approval status
          not_reconciled
          duplicate text group
          dup-1209645c66a5a2dd097c
          extraction review status
          automated_candidate_pending_source_review
          generic names
          1. SONIDEGIB
          id
          ind-span-2783a18499d757f5b95c
          label id
          001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
          positive predicate support span
          end
          313
          end exclusive
          true
          exact text
          is a hedgehog pathway inhibitor indicated
          label id
          001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          dc49031419063786378da2b1d31302a59db03f1835264ddf9da927f914602e6c
          start
          272
          qualifier mentions
          1. context exact
            a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has r
            kind
            age
            polarity
            not_inferred
            span
            end
            349
            end exclusive
            true
            exact text
            adult patients
            label id
            001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            dc49031419063786378da2b1d31302a59db03f1835264ddf9da927f914602e6c
            start
            335
          2. context exact
            nhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those
            kind
            stage_or_setting
            polarity
            not_inferred
            span
            end
            406
            end exclusive
            true
            exact text
            locally advanced basal cell carcinoma (BCC) that ha
            label id
            001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            dc49031419063786378da2b1d31302a59db03f1835264ddf9da927f914602e6c
            start
            355
          regulatory links
            schema version
            0.1.0
            source batch sha256
            0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
            source defined aliases
              source span
              end
              522
              end exclusive
              true
              exact text
              ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
              label id
              001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              dc49031419063786378da2b1d31302a59db03f1835264ddf9da927f914602e6c
              start
              265
              source url
              https://api.fda.gov/drug/label.json?search=id%3A%22001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3%22
              spl effective date
              2024-12-31
              spl set id
              028312dc-d155-4fd5-8abd-6bb9f011d3cc
              spl version
              14
              structured fields status
              not_extracted_no_values_inferred_from_mentions
              structured indication
              age
              Source null
              approval pathway
              Source null
              biomarker and test
              Source null
              disease stage
              Source null
              limitations
              Source null
              line
              Source null
              prior therapy
              Source null
              regimen
              Source null
              tumor histology
              Source null
              use intent
              tumor_directed_candidate
              Passage 3 · unclassified context
              application numbers
              1. NDA205266
              brand names
              1. Odomzo
              classification reasons
              1. no_unambiguous_positive_indication_predicate
              clinical review status
              pending
              content role
              unclassified_context
              context span
              end
              528
              end exclusive
              true
              exact text
              reatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ( 1 )
              label id
              001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              dc49031419063786378da2b1d31302a59db03f1835264ddf9da927f914602e6c
              start
              323
              current approval status
              not_reconciled
              duplicate text group
              dup-f364eecef44447cd8fdf
              extraction review status
              automated_candidate_pending_source_review
              generic names
              1. SONIDEGIB
              id
              ind-span-9c3e21744c46f1b93d7f
              label id
              001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
              positive predicate support span
              Source null
              qualifier mentions
                regulatory links
                  schema version
                  0.1.0
                  source batch sha256
                  0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
                  source defined aliases
                    source span
                    end
                    528
                    end exclusive
                    true
                    exact text
                    ( 1 )
                    label id
                    001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    dc49031419063786378da2b1d31302a59db03f1835264ddf9da927f914602e6c
                    start
                    523
                    source url
                    https://api.fda.gov/drug/label.json?search=id%3A%22001dc6f2-7476-4ffd-8ea4-be2f97a2b6b3%22
                    spl effective date
                    2024-12-31
                    spl set id
                    028312dc-d155-4fd5-8abd-6bb9f011d3cc
                    spl version
                    14
                    structured fields status
                    not_extracted_no_values_inferred_from_mentions
                    structured indication
                    age
                    Source null
                    approval pathway
                    Source null
                    biomarker and test
                    Source null
                    disease stage
                    Source null
                    limitations
                    Source null
                    line
                    Source null
                    prior therapy
                    Source null
                    regimen
                    Source null
                    tumor histology
                    Source null
                    use intent
                    unclear

                    Preserved source evidence · Not medical advice